The Trump administration has issued a waiver allowing the distribution of lifesaving HIV medications, offering a temporary reprieve for the President’s Emergency Plan for AIDS Relief (PEPFAR), which was abruptly halted last week. However, it remains unclear whether the waiver extends to preventive drugs and other essential services.
PEPFAR’s potential collapse threatens the treatment of over 20 million people, including 500,000 children. Without access to medication, millions living with HIV, particularly in low-income countries, face the risk of full-blown AIDS and premature death. Experts warn that the situation could mirror the devastating HIV epidemic of the 1980s.
On Monday, the administration ordered health organisations abroad to cease distributing HIV medications purchased with U.S. funds, following a freeze, potentially permanent, on PEPFAR’s $7.5 billion operations. Since its launch in 2003, the programme has saved an estimated 25 million lives and prevented the transmission of HIV to 5.5 million children. In South Africa alone, shutting down PEPFAR could result in over 500,000 new infections and 600,000 deaths in the next decade.
The suspension has disrupted healthcare systems, with 270,000 doctors, nurses, and other health workers instructed not to report to work. Dr. Salim Abdool Karim of the University of KwaZulu-Natal cautioned that the abrupt withdrawal of PEPFAR could destabilise national AIDS programmes, potentially leading to their collapse. While advocating for greater self-reliance, he stressed the need for a gradual transition rather than a sudden and unplanned withdrawal of support.
Every day, more than 220,000 people, including 7,400 children under 15, receive HIV medications from PEPFAR-funded clinics. Without treatment, the virus rapidly rebounds, weakening the immune system and increasing the risk of opportunistic infections such as tuberculosis. Moreover, untreated individuals are more likely to transmit the virus to others. Experts warn that as people ration or share their remaining medication, the emergence of drug-resistant strains will pose a significant challenge, not only in low-income countries but globally.
Beyond treatment, PEPFAR supports HIV prevention, testing, and services for vulnerable populations, including orphans and survivors of gender-based violence. The loss of these resources will severely undermine efforts to control the epidemic. If HIV testing declines, undiagnosed individuals will miss critical early interventions, increasing transmission risks, particularly among pregnant and breastfeeding mothers who could unknowingly pass the virus to their children.
The global ramifications extend beyond HIV. Large numbers of immunocompromised individuals create an environment for new infectious disease threats, as seen with the evolution of COVID-19 variants like Omicron in HIV-positive populations. Additionally, drug-resistant HIV strains could undermine existing treatments and compromise vaccine development.
The United States has long been recognised for its humanitarian leadership through PEPFAR, earning goodwill worldwide. Experts argue that allowing the programme to collapse is not only a public health disaster but also a strategic and diplomatic misstep. Dr. Steve Deeks of the University of California, San Francisco, summed up the sentiment: From a humanitarian perspective, this doesn’t make sense on any level.
